Product name: Fallaxsaponin A
Synonym name: Polygalic acid 3-O-β-D-glucoside; Senegenic acid 3-O-β-D-glucoside
Catalogue No.: BP5186
Cas No.: 1287702-60-6
Formula: C₃₅H₅₄O₁₁
Mol Weight: 650.806
Botanical Source:
Type of Compound: Triterpenoids

Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle

Storage: Store in a well closed container, protected from air and light. Put into refrigerate or freeze for long term storage.
Whenever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20℃. Generally, these will be useable for up to two weeks.

The product could be supplied from milligrams to grams
Inquire for bulk scale.

For Reference Standard and R&D, Not for Human Use Directly.

NMR of Fallaxsaponin A

HPLC of Fallaxsaponin A

Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃

Introduction/Overview

Fallaxsaponin A is a natural triterpene saponin compound extracted from the roots of Polygala tenuifolia Willd. As a traditional Chinese medicinal herb, Polygala has long been renowned for its calming and soothing effects, as well as its phlegm-resolving and opening the orifices, and is widely used in the treatment and research of neurological and inflammation-related diseases. In recent years, with the development of natural product pharmacology, Tianhua Dao Shuishui Shuisei Saponin A has become a research hotspot due to its significant anti-inflammatory activity and relatively good safety. Based on existing literature, this paper systematically reviews the chemical structure and physicochemical properties of Tianhua Daoshuilian Saponin A, plant origin and extraction methods, pharmacological activity and mechanism of action, druggability evaluation, and pharmacokinetic characteristics, exploring its clinical application prospects and future research directions.

Chemical structure and physicochemical properties

The molecular formula of Tianhua Daoshuilian Saponin A is C_36H_58O_11, with a molecular weight of 650.8060, making it a natural product of the triterpene saponins. Its structural features include a typical five-ring triterpene backbone connecting multiple glycosyl residues, giving it high polarity and water solubility. The compound has a LogP value of 2.6311, indicating moderate lipid solubility, which facilitates penetration of cell membranes. The total polar surface area (TPSA) is 194.2100, indicating the presence of numerous polar groups such as hydroxyl and glycosyls on the molecular surface, enhancing its water solubility (0.1220), but also limiting its ability to cross the blood-brain barrier, which has low permeability.

Daylily Daoshitian saponin A does not inhibit hERG channels, indicating a low risk of cardiotoxicity; The Ames test result was 0.0, indicating no significant genotoxicity risk. These physicochemical and safety parameters provide a solid foundation for further drug development.

Plant Origins and Extraction Methods

Huanghua Daoshuilian saponin A is mainly isolated from Polygala root. Polygala belongs to the Polygala family, widely distributed in northern China and East Asia, and is an important part of traditional Chinese medicine. Its roots are rich in triterpene saponins, polysaccharides, flavonoids, and various alkaloids, serving as the main source of saponin compounds.

The extraction process typically uses ethanol or methanol as solvent for reflux extraction, followed by liquid-liquid partitioning, silica gel column chromatography, and reversed-phase high-performance liquid chromatography (RP-HPLC) for purification. For the isolation of Ponian saponin A from daylilies, researchers mostly use water-ethanol mixed solvent systems for extraction, combined with silica gel column chromatography and preparative HPLC technology to ensure compound purity and activity. In recent years, ultrasound-assisted extraction and microwave-assisted extraction technologies have also been applied to improve extraction efficiency and purity.

Pharmacological activity research

Research on the pharmacological activity of Huanghua Daoshuilian Saponin A has mainly focused on its anti-inflammatory effects. Both in vitro and in vivo experiments have shown that this compound can significantly inhibit the expression and release of various inflammatory mediators, reducing inflammatory responses.

At the cellular level, daylily saponin A can inhibit the expression of pro-inflammatory cytokines such as tumor necrosis factor α (TNF-α), interleukin-6 (IL-6), and induced nitric oxide synthase (NOS2) in macrophages and other immune cells, reducing the release of inflammatory mediators. In animal models, daylily Daoshui Shuisei saponin A demonstrated effects in reducing inflammatory edema and inhibiting inflammatory cell infiltration and tissue damage, indicating its potential anti-inflammatory therapeutic value.

Additionally, some studies have reported its regulatory effects on neuroinflammation, suggesting that this compound may play a protective role in neurodegenerative and chronic inflammatory diseases.

Mechanism of action and molecular targets

The anti-inflammatory mechanism of Tianhua Daoshitian saponin A involves multiple signaling pathways and molecular targets. Its main targets include:

• IL-6 (Interleukin 6): As a pro-inflammatory cytokine, IL-6 plays a key role in the inflammatory response. Daylily Daoshitsu saponin A can downregulate IL-6 expression and weaken inflammatory signaling.
• STAT3 (Signal Transduction and Transcription Activator 3): STAT3 is a key transcription factor in the IL-6-mediated signaling pathway, regulating the expression of various inflammatory genes. This compound blocks the cascade of inflammatory signals by inhibiting STAT3 activation.
• CASP1 (Caspase 1): CASP1 is involved in the formation of inflammatory bodies and the maturation of pro-inflammatory cytokines. Tianhua Dao Shuisei Saponin A inhibits its activity, reducing the release of inflammatory mediators.
• TRPV1 and TRPA1 (Transient Receptor Potential Channels): These two ion channels play important roles in inflammatory pain and neuroinflammation. Daylily Saponin A can regulate its activity and relieve inflammation-related pain.
• PTGS1 (cyclooxygenase 1) and PTGS2 (cyclooxygenase 2): As key enzymes in prostaglandin synthesis, PTGS2 is highly induced in inflammation. This compound inhibits the expression of PTGS2 and reduces the synthesis of pro-inflammatory prostaglandins.
• TNF (tumor necrosis factor): TNF is the main pro-inflammatory factor, and daylily saponin A can reduce its production and lessen inflammatory responses.
• NOS2 (induced nitric oxide synthase): NOS2 catalyzes nitric oxide production and participates in inflammatory responses. This saponin reduces the accumulation of inflammatory mediators by inhibiting NOS2 expression.
• NFKB1 (nuclear factor κB): NF-κB is a core transcription factor regulating inflammatory gene expression. The saponin A of the daylily inhibits its activation and blocks inflammatory signaling.

In summary, Tianhua Daoshui Shuisei Saponin A regulates inflammatory responses through multiple targets and pathways, demonstrating broad-spectrum anti-inflammatory potential.

Druggability evaluation and pharmacokinetics

The druggability evaluation of Tianhua Daoshuilian Saponin A indicates good safety and moderate drug properties. The molecular weight of 650.8060 is slightly above the ideal range for traditional small molecule drugs, but its LogP value of 2.6311 meets the lipid solubility requirements of the drug, which is beneficial for distribution in the body. TPSA is relatively high, reflecting strong polarity and moderate water solubility (0.1220), which may affect oral absorption rates.

The low permeability of the blood-brain barrier suggests its direct role in the central nervous system is limited, but this also reduces the risk of central toxicity. The Ames test, which showed no hERG channel inhibition and negative results, indicated that it carries low risks of cardiotoxicity and genotoxicity, and is relatively safe.

Currently, pharmacokinetic research on the pharmacokinetic effects of Hydroponin A in Yellow Flower is relatively limited. Preliminary in vivo experiments indicate that the compound is absorbed slowly after oral administration and has limited bioavailability, possibly related to its high polarity and large molecular weight. The metabolic pathway mainly involves liver enzyme systems, undergoing glycoside hydrolysis and redox reactions. Excretion is mainly carried out through bile and urine. In the future, systematic pharmacokinetic and toxicological studies are needed to improve druggability evaluation.

Prospects and outlooks for clinical applications

As a natural product with multi-target anti-inflammatory activity, Tianhua Daoshuilian Saponin A demonstrates promising clinical application potential. It has significant application prospects in chronic inflammatory diseases (such as rheumatoid arthritis and inflammatory bowel disease), neuroinflammation, and pain management. Especially in inflammation-related neurodegenerative diseases such as Alzheimer's and Parkinson's disease, its regulation of the TRPV1/TRPA1 channel and its role in inhibiting neuroinflammation warrant further study.

However, current clinical research on Tianhua Dao Shuisei Saponin A is still in its early stages and lacks systematic clinical trial data. Future research should focus on the following directions:

1. Pharmacokinetics and pharmacodynamics studies: clarify the absorption, distribution, metabolism, and excretion characteristics in the body, and optimize administration regimens.
2. Dosage Form Development and Drug Delivery: To address water solubility and bioavailability, develop new dosage forms or nano delivery systems to improve efficacy and targeting.
3. Clinical safety and efficacy evaluation: Conduct systematic preclinical toxicology studies and clinical trials to verify safety and efficacy.
4. In-depth mechanism analysis: Using modern molecular biology and omics techniques, further elucidating its anti-inflammatory and neuroprotective mechanisms, expanding indications.

Through multidisciplinary collaboration, Huanghua Daoshui Shuisenin A is expected to become a candidate molecule for novel anti-inflammatory drugs, promoting clinical translation of natural product pharmacology.

Conclusion

Polygonum saliflora saponin A, an important triterpene saponin isolated from Polygala root, holds significant research value in the field of natural product pharmacology due to its remarkable anti-inflammatory activity and good safety. Its multi-target and multi-pathway mechanism of action provides a theoretical basis for the development of novel anti-inflammatory drugs. Although pharmacokinetics and clinical research are still insufficient, by optimizing extraction and purification processes, in-depth pharmacological research, and systematic druggability evaluation, Tianhua Dao Shuisei Saponin A is expected to become an emerging drug in future anti-inflammatory treatment. Future research should focus on its clinical translation pathway, promoting it from the laboratory to clinical applications to benefit patients.